Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15778027 | 0.87 | EPAS1 (0.38) | HRH4RAD51TRPV4TRPA1SCN5A | |
| SCHEMBL29354273 | 0.87 | EPAS1 (0.38) | HRH4RAD51TRPV4TRPA1SCN5A | |
| SCHEMBL5043182 | 0.80 | APP (0.42) | TRPV4ALDH1A1APPL3MBTL1 | |
| SCHEMBL4600184 | 0.79 | KIF11 (0.43) | TRPA1SCN5ASCN9AALDH1A1EPAS1 | |
| SCHEMBL2463638 | 0.79 | PDE4A (0.41) | RAD51TRPV4ALDH1A1EPAS1CA1 | |
| SCHEMBL2464656 | 0.79 | PDE3B (0.37) | HRH4NTRK1BACE2MAOAMAOB | |
| SCHEMBL29955071 | 0.78 | ALDH1A1 (0.58) | RAD51ALDH1A1L3MBTL1 | |
| SCHEMBL1398327 | 0.78 | ALDH1A1 (0.58) | RAD51ALDH1A1L3MBTL1 | |
| SCHEMBL28194011 | 0.76 | HRH4 (0.41) | HRH4TRPV4TRPA1SCN5ASCN9A | |
| SCHEMBL1220795 | 0.76 | ALDH1A1 (0.40) | HRH4ALDH1A1MAOAMAOBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115403570-B | Mu-opioid receptor agonist, preparation method thereof and application thereof in medicine field | 上海华汇拓医药科技有限公司 | 2024-10-22 | — | — | CN | disclosed |
| WO-2022268066-A1 | PROTEIN DEGRADATION AGENT | 苏州开拓药业股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| EP-3686198-B1 | MU-OPIOID RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF IN FIELD OF MEDICINE | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO LTD (CN) | 2022-12-14 | — | — | EP | disclosed |
| CN-115403570-A | Mu-opioid receptor agonist, preparation method thereof and application thereof in medicine field | 上海华汇拓医药科技有限公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-109516982-B | Mu-opioid receptor agonist, preparation method thereof and application thereof in medicine field | 上海华汇拓医药科技有限公司 | 2022-08-23 | — | — | CN | disclosed |
| US-11072601-B2 | μ-opioid receptor agonist and preparation method therefor and use thereof in field of medicine | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD. (CN) | 2021-07-27 | — | — | US | disclosed |
| US-20200270230-A1 | µ-OPIOID RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF IN FIELD OF MEDICINE | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2020-08-27 | — | — | US | disclosed |
| EP-3686198-A1 | mu-OPIOID RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF IN FIELD OF MEDICINE | Shanghai Synergy Pharmaceutical Sciences Co., Ltd (CN) | 2020-07-29 | — | — | EP | disclosed |
| EP-2035419-B1 | 5-ARYL-SUBSTITUTED DIHYDROPYRIDOPYRIMIDINES AND DIHYDROPYRIDAZINES AND USE THEREOF AS MINERAL CORTICOID ANTAGONISTS | BAYER IP GMBH (DE) | 2016-06-22 | — | — | EP | disclosed |
| EP-2035419-B1 | 5-ARYL-SUBSTITUTED DIHYDROPYRIDOPYRIMIDINES AND DIHYDROPYRIDAZINES AND USE THEREOF AS MINERAL CORTICOID ANTAGONISTS | BAYER IP GMBH (DE) | 2016-06-22 | — | — | EP | disclosed |
| EP-2132206-A2 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINAMIDES AND USE THEREOF | Bayer Schering Pharma AG (DE) | 2009-12-16 | — | — | EP | disclosed |
| EP-2035419-A1 | 5-ARYL-SUBSTITUTED DIHYDROPYRIDOPYRIMIDINES AND DIHYDROPYRIDAZINES AND USE THEREOF AS MINERAL CORTICOID ANTAGONISTS | Bayer HealthCare AG (DE) | 2009-03-18 | — | — | EP | disclosed |
| EP-2029591-A1 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF | Bayer HealthCare AG (DE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2008104306-A2 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINAMIDES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104306-A2 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINAMIDES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008034534-A1 | 3-CYANO-5-THIAZAHETEROARYL-DIHYDROPYRIDINE AND THE USE THEREOF FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007140934-A1 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007140934-A1 | SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007140894-A1 | 5-ARYL-SUBSTITUTED DIHYDROPYRIDOPYRIMIDINES AND DIHYDROPYRIDAZINES AND USE THEREOF AS MINERAL CORTICOID ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007140894-A1 | 5-ARYL-SUBSTITUTED DIHYDROPYRIDOPYRIMIDINES AND DIHYDROPYRIDAZINES AND USE THEREOF AS MINERAL CORTICOID ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072601-B2 | μ-opioid receptor agonist and preparation method therefor and use thereof in field of medicine | OPRM1, OPRD1, OPRK1 | HRH4 509/4885RAD51 4415/4885TRPV4 243/4885 |
| US-20200270230-A1 | µ-OPIOID RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF IN FIELD OF MEDICINE | OPRM1, OPRD1, OPRK1 | HRH4 474/4885RAD51 4388/4885TRPV4 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.